Daily Stock List
Cosmos Holdings, Inc. (COSM)
TopPennyStockMovers and OTC Markets Group reported previously on Cosmos Holdings, Inc. (COSM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Cosmos Holdings, Inc. is a fully reporting International Holding company listed on the OTC Markets Group’s OTCQB. It conducts its business within the pharmaceutical industry. Cosmos currently has one wholly-owned subsidiary, SkyPharm. Sky Pharm trades the excess amounts of approximately 500 medicines, which can be exported within the European Union (EU) countries. Cosmos Holdings has its corporate headquarters in Chicago, Illinois. Its warehouse and distribution center is in Thessaloniki, Greece.
Cosmos Holdings is presently focusing its existing operations on expanding the business of SkyPharm S.A. The Company has concentrated its efforts on becoming a worldwide pharmaceutical enterprise. Cosmos’ emphasis will be on Branded Pharmaceuticals, Over-the-Counter (OTC) medicines, Generic Pharmaceuticals, Cosmetics Products & Food Supplements, Research & Development (R&D), as well as Growth Opportunities.
Cosmos looks to continue to enhance its pharmaceutical and OTC product lines through acquiring or licensing rights to additional products. In addition, the Company looks to regularly evaluate selective acquisition and license opportunities.
Cosmos Holdings earlier further equipped a warehouse for medicines for its subsidiary SkyPharm in Thessaloniki. As of July 22, 2015, the Hellenic Ministry of Health, and more specifically the National Organization for Medicines, granted the license for the wholesale of pharmaceutical products for human use to SkyPharm. The license is valid for a period of five years.
Cosmos’ commitment is to pursuing different types of business development. The Company states that this can include trading, alliances, licenses, joint ventures (JVs), dispositions and acquisitions. Cosmos also hopes to continue to build on its portfolio of pharmaceutical products and expand its product pipeline to generic and cosmetics products.
Basically, Cosmos Holdings centers on identifying, acquiring, developing, and commercializing different medicines to improve patients’ lives. The Company has a large network of more than 60 clients and vendors in Germany, the United Kingdom (UK), Ireland, Denmark, Poland, Netherlands, and Greece.
Regarding Q3 2016, Cosmos Holdings’ sales and operating margins continued to improve from Q2 to Q3 of Fiscal Year 2016. Sales grew from $956k to $1,414k from Q2 2016 to Q3 2016 respectively. This represents a more than 47 percent increase. This increase was because of organic growth in the sales from its subsidiary Sky Pharm SA. Moreover, gross operating margins improved from Q2 2016 to Q3 2016.
Cosmos Holdings, Inc. (COSM), closed Tuesday's trading session at $0.775, up 0.65%, on 9,000 volume with 11 trades. The average volume for the last 60 days is 8,461 and the stock's 52-week low/high is $0.32/$0.80.
GrowBLOX Sciences, Inc. (GBLX)
CFN Media Group, AllPennyStocks, Stockgoodies, SmallCapVoice, Cannabis Financial Network News, StocksToBuyNow, Tip.us, Money Morning, SeriousTraders, Otcstockexchange, PennyStockInformer, Whisper from Wall Street, PennyStockLaboratory, Wall Street Resources, Wall St Report, and Pumps and Dumps, reported earlier on GrowBLOX Sciences, Inc. (GBLX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
GrowBLOX Sciences, Inc. is a biopharmaceutical research and development (R&D) company. Its focus is on creating safe, standardized, pharmaceutical-grade, cannabinoid therapies, which target an assortment of medical conditions. The Company is developing and internationally distributing its GrowBLOX ™ set of cultivation and growing chambers.
GrowBLOX Sciences is based in Las Vegas, Nevada. The Company’s wholly-owned subsidiary is GB Sciences. Moreover, GrowBLOX Sciences has formed Growblox Life Sciences, LLC (a wholly-owned subsidiary) to pursue development of its intellectual property (IP) related to innovative cannabis-based medical compounds.
GrowBLOX Sciences has developed proprietary indoor growing chambers specifically designed for medical cannabis cultivation. It is working to set the standard for manufacturing medical cannabis producing technology, and discovering, developing, and commercializing proprietary strains of cannabis to treat a wide spectrum of serious medical conditions.
The Company’s GrowBLOX technology suite includes the TissueBLOX, GrowBLOX, CureBLOX, and ExtractionLAB equipment. Its GrowBLOX chamber allows for completely controlled growing conditions. As a result, this ensures the manufacture of a consistent, toxin-free, natural and medicinal-grade product.
The GrowBLOX™ Controlled Environment Agricultural Chambers (GrowBLOX™) is the first chamber of its type that can monitor and control the growth process to produce high-grade medicinal marijuana. Regarding its GrowBLOX™ Nutrient System, the Company provides growers with premium blends of nutrients containing 100 percent natural water-soluble nutrients designed for use with its advanced AeroVAPOR™ misting system.
GrowBLOX Sciences’ formulas contain all the essential minerals cannabis plants need for optimal growth. Its intelligent control system ensures that growers know the optimal time, quantity, and type of nutrients to add to the AeroVAPOR™ unit. This eliminates any guesswork.
Recently, GrowBLOX announced that it acquired two additional Medical Marijuana Establishment (MME) licenses in Clark County, Nevada. The Company has formed GB Sciences Las Vegas, LLC. to acquire these two licenses. Growblox will be the owner/operator of the businesses and own 60 percent of the entity with the option to own up to 80 percent.
Last week, GrowBLOX announced that Growblox Life Sciences licensed IP from Makai Biotechnology, LLC. The patent underlying the license was issued by the United States Patent and Trademark Office (USPTO) in July of 2015, and claims therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies via regulation of the cannabinoid receptor, TRPV1. TRPV1 can be regulated therapeutically by plant-based cannabinoids, which creates an abundance of potentially new therapeutic agents for the treatment of cardiac hypertrophy and heart failure.
GrowBLOX Sciences, Inc. (GBLX), closed Tuesday's trading session at $0.30, up 0.67%, on 256,485 volume with 60 trades. The average volume for the last 60 days is 1,020,498 and the stock's 52-week low/high is $0.11/$0.65.
eWellness Healthcare Corp. (EWLL)
StockHideout and Penny Stock Prodigy reported recently on eWellness Healthcare Corp. (EWLL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Culver City, California-based, eWellness Healthcare Corp. develops a telemedicine platform. This platform is for providing Distance Monitored Physical Therapy programs. These programs are for pre-diabetic, cardiac, and health challenged patients by way of contracted physician practices and healthcare systems. The Company has launched PHZIO. The design of this telemedicine platform is to extend and scale a physician’s practice. eWellness Healthcare lists on the OTC Markets’ OTCQB.
eWellness Healthcare is the first physical therapy telemedicine company to offer insurance reimbursable real-time distance monitored treatments. Its business model is to license its PHZIO platform to any physical therapy (PT) clinic in the U.S.A. and/or have large-scale employers utilize its PHZIO platform as a fully PT monitored corporate wellness program.
Basically, eWellness Healthcare’s PHZIO is a Physical Therapy Telemedicine platform. It extends a traditional practice online. The chief features of the PHZIO platform include video treatment protocols, real-time patient monitoring, patient induction forms, a patient video journal, and post treatment evaluations. Principal features also include integrated billing, patient metrics, and user administration & customization.
Additionally, PHZIO scales a practice’s billable rates. It also provides tools to make growing a business easier. Concerning the Patient Dashboard, the PHZIO Dashboard enables clients to login securely to access prescribed treatment protocols. PHZIO is user-friendly, highly reliable to operate (for PT and Patient). Furthermore, it’s a comprehensive on-line PT telemedicine intervention system.
eWellness Healthcare is launching a complete corporate wellness program using its 6-month PHZIO distance monitored exercise program to around 100 employees at a Los Angeles, California based university. The top line wellness objectives of the Company’s PHZIO program is to graduate a minimum 80 percent of inducted patients via its 6-month program.
On October 21, 2016, eWellness Healthcare announced that it successfully held its commercial launch of its PHZIO PT telemedicine intervention system as a Tier 1 sponsor of the American Physical Therapy Association (APTA), Private Practice Section (PPS) Annual Conference held in Las Vegas, Nevada.
Last week, eWellness Healthcare announced that it successfully signed another third-party PT clinic for the use of its PHZIO Tele-health Platform. The agreement is with a well-known Brooklyn based PT clinic, owned by Motion PT Group. Their Brooklyn based clinic is one of more than 45 clinics now owned by Motion PT Group.
Today, eWellness Healthcare announced that it successfully launched a new PHZIO PT clinic on-boarding website. The portal includes a telehealth profitability calculator to illustrate to prospective PT clinics the additional profits they can make through using the PHZIO platform.
eWellness Healthcare Corp. (EWLL), closed Tuesday's trading session at $0.18447, up 12.14%, on 2,056,338 volume with 381 trades. The average volume for the last 60 days is 1,815,151 and the stock's 52-week low/high is $0.0057/$4.00.
Cellceutix Corp. (CTIX)
AllPennyStocks, The Observer, Stock Gumshoe, Promotion Stock Secrets, Streetwise Reports, and StreetAuthority Financial reported earlier on Cellceutix Corp. (CTIX), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Cellceutix Corp. is developing unique therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications. A clinical stage biopharmaceutical company, Cellceutix has established research collaborations with world-renowned research institutions in the United States and Europe. These include MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. Cellceutix is headquartered in Beverly, Massachusetts.
The Company’s anti-cancer drug Kevetrin (a Novel p53-modulating drug candidate) concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. It anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction.
Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the Food and Drug Administration (FDA)-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria.
Earlier this month, Cellceutix announced the initiation of the second cohort of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD). Review of safety data from the first cohort showed that Brilacidin, administered for 6 weeks as a retention enema, at 50 mg once daily, appeared well-tolerated, with no measurable systemic absorption detected. The continuing Phase 2, open-label, proof-of-concept clinical trial is evaluating Brilacidin for induction of remission, not just maintenance, in patients suffering from mild-to-moderate UP/UPS.
Last week, Cellceutix announced the selection of Contract Research Organizations (CROs) to start more nonclinical studies to support the potential transition to oral dosing of Kevetrin for ovarian cancer. Cellceutix reported advances in developing Kevetrin as an oral ovarian cancer treatment. The Company is looking to develop the world’s first p53-modulating oral cancer drug.
Yesterday, Cellceutix announced that 24 of the 25 (all U.S.-based) core Phase 2b clinical trial sites for oral Prurisol in the treatment of moderate-to-severe psoriasis have now been started. They are open for screening, with the last site expected to follow later this week. The availability of the additional sites beyond those that have already started to treat active study participants is expected to considerably facilitate timely completion of full enrollment.
Cellceutix Corp. (CTIX), closed Tuesday's trading session at $1.16, down 0.85%, on 219,797 volume with 230 trades. The average volume for the last 60 days is 143,261 and the stock's 52-week low/high is $0.91/$1.92.
Abattis Bioceuticals Corp. (ATTBF)
CFN Media Group, Goldman Small Cap Research, Promotion Stock Secrets, Stockgoodies, InvestorIntel, Cannabis Financial Network News, Greenbackers, PennyStocks24, and Information Solutions Group reported on Abattis Bioceuticals Corp. (ATTBF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.
Abattis Bioceuticals Corp. is a specialty, vertically-integrated biotechnology company. It aggregates, incubates, integrates, and also invests in the botanical drug development industry. It previously went by the name Abattis Biologix Corporation. It changed its corporate name to Abattis Bioceuticals Corp. in September of 2012. The Company is headquartered in Vancouver, British Columbia.
Abattis’ divisions include Biocell Labs, Inc. and Vergence Sales & Marketing, Inc. Through these, it develops and licenses natural health products. As well, the Company’s other divisions are Northern Vine Canada, Inc.; North American Bioextracts, Inc.; and Biocube Green Grow Systems Corp.
Abattis has made investments in companies such as Phytalytics (51 percent), IPS (51 percent) and Experion (25 percent). Consequently, Abattis has capabilities that support the production and extraction of botanical ingredients for its products; one of which includes cannabis.
Abattis Bioceuticals develops and licenses natural health products, medicines, extractions, and ingredients - some of which will contain cannabinoid compounds. These are for the biologics, nutraceutical, bioceutical, and cosmetic markets. Also, the Company has a wide-ranging pipeline of high-quality products and intellectual property (IP) for the fast-growing botanical drug market.
Abattis Bioceuticals’ products and services include Botanical Blends & Formulas; CBD Ingredients; Functional Foods & Beverages; Research and Development (R&D); Analytical Services; and Pharma & Nutraceuticals. The Company has received a Natural Product Number (NPN) approval for Phyto(NOS). This NPN permits it to manufacture and sell Phyto(NOS) in Canada. Ingredient Identity of Santa Ana, California, completed the claim substantiation report required for the sale of Phyto(NOS)™ in the U.S.
Phyto(NOS) has applications in a broad array of food, beverage, and nutraceutical products. Phyto(NOS) is an all-natural, patent-pending formulation. It naturally supports nitric oxide (a vasodilator) levels in the blood stream, supports nitric oxide production, and provides antioxidants.
Abattis Bioceuticals has entered into a Memorandum of Understanding (MOU) with Global Damon Pharma (GDP) of South Korea, to distribute and sell Abattis' proprietary PhytoNOS™ and Sassy™ Tonics in modified formulations. GDP will involve in the research and creation of required components for completion of these two products. Additionally, GDP will negotiate and enter into a formal Exclusive Licensing Agreement to sell and distribute these two products under license in South Korea.
Recently, Abattis Bioceuticals announced that it and Northern Vine entered into a Binding Memorandum of Agreement with Experion Biotechnologies to acquire up to 100 percent of Experion Biotechnologies, Inc. Abattis Bioceuticals and its subsidiary Northern Vine Canada, Inc., expect to advance up to $5 million in the near term and $2.5 million in deferred capital to implement lab expansion and increase Abattis' proportionate share of Experion Biotechnologies. Last month, Abattis Bioceuticals announced the renewal of the Health Canada License for the Northern Vine Canada testing lab.
Abattis Bioceuticals Corp. (ATTBF), closed Tuesday's trading session at $0.10, down 9.09%, on 476,777 volume with 41 trades. The average volume for the last 60 days is 508,363 and the stock's 52-week low/high is $0.015/$1.00.
Monaker Group, Inc. (MKGI)
The QualityStocks Daily Newsletter would like to spotlight Monaker Group, Inc. (MKGI). Today, Monaker Group, Inc. closed trading at $2.02, up 1.00%, on 20,736 volume with 29 trades. The stock’s average daily volume over the past 60 days is 10,710, and its 52-week low/high is $1.10/$5.00.
Monaker Group, Inc. today released a "Shareholder Update". Key highlights include:
• Proprietary booking engine is completed and conforms to all Online Travel industry standards allowing for easy business to business integration.
• Over 1 million "real-time" bookable properties integrated and more than 2 million ALR properties under contract.
• Company anticipates Roll-out of Business Travel Partners and NextTrip.com consumer platform in January 2017.
• The NextTrip site will be industry leader with real-time bookable properties and a host of travel products and services allowing for "one-stop" travel shopping.
• Mobile App for both Android and IOS versions scheduled for end of January 2017.
Monaker Group, Inc. (MKGI) is a technology driven travel company focused on leveraging resources to become a significant presence in the fastest growing sector of the $1.3 trillion travel and tourism market. The company's flagship brand, NextTrip.com, is the industry's first and only real-time booking engine that features alternative lodging (vacation home rentals, resort residences and unused timeshare inventory), as well as a full selection of airlines, hotels, cruises, rental cars, tours and concierge services. These features are combined into a single, easy-to-use platform that gives travelers complete real-time control when planning and booking their vacations.
NextTrip.com takes an integrated approach to the needs of travelers by combining multiple booking solutions into a highly intuitive real-time booking platform. Since its launch in February 2016, NextTrip has already grown to more than 250,000 units of vacation rental inventory. Monaker currently has roughly 1 million additional alternative lodging units under contract that will soon be added to the platform. This will place NextTrip among the top three largest vacation rental inventories and rival industry peers, Airbnb and HomeAway, in the rapidly expanding alternative lodging market. Unlike the competition, which book by request which can take hours or days before a lodging owner confirms, NextTrip's platform books in real-time, similar to online hotel bookings.
Most NextTrip listings are in desirable locations in the U.S., the EU and the Caribbean with about 20% exclusive listings. Monaker expects rapid exclusive listing growth because, unlike the competition, Monaker doesn't charge a sign-up fee, just a commission upon booking. The competition charges both. Monaker even has a proprietary solution to unlock Timeshare and Fractional Share properties as rental inventory.
Through strategic partnerships and acquisitions Monaker is now positioned to be a major player in the travel and alternative lodging sector. In addition Monaker is also the parent to Maupintour and Voyage TV.
In business for 65 years, Maupintour still leads the tour industry in the creation of outstanding, unique itineraries and has the highest repeat rate in the tour industry. Maupintour's upscale luxury services create a unique blend with the various product offerings of NextTrip. Voyage TV has thousands of hours of travel footage shot in over 30 countries worldwide. These 15,000 video clips of hotels, resorts, cruise, and destination activities are a treasure trove for vacation travel marketing.
With an established portfolio of travel brands, and a proven record acquiring, consolidating and integrating companies, Monaker is building a diverse and exciting foundation to drive the company's future. According to data from the U.S. Travel Association, direct spending on leisure travel by domestic and international travelers topped $650 billion in 2015. When combined with the fact that roughly 64 percent of travel companies are still considered small businesses, Monaker's all-inclusive approach to vacation booking through NextTrip and Maupintour strategically positions it for sustainable growth moving forward.
Monaker is headquartered in South Florida with offices in California. The company is led by a seasoned management team with decades of applicable industry experience. Monaker's Chairman and Chief Executive Officer Bill Kerby has over 18 years of experience in the media and travel industries, as well as 10 years of experience in the financial industry. Disclaimer
Monaker Group, Inc. Company Blog
Monaker Group, Inc. News:
Monaker Group Shareholder Update -- 2016 Milestones and Transactional Business
Monaker Group (MKGI): Tip of the Travel Industry Iceberg -- SECFilings.com
Recruiter.com Launches Custom Travel & Loyalty Program via Monaker Group Partnership
National Waste Management Holdings, Inc. (NWMH)
The QualityStocks Daily Newsletter would like to spotlight National Waste Management Holdings, Inc. (NWMH). Today, National Waste Management Holdings, Inc. closed trading at $0.0626, up 3.99%, on 9,086 volume with 7 trades. The stock’s average daily volume over the past 60 days is 13,850, and its 52-week low/high is $0.06/$1.50.
National Waste Management Holdings, Inc. (NWMH) is a solid waste management company offering comprehensive solutions for full waste diversion along Florida's west coast and in upstate New York. With an established base of long-term partnerships with municipal, institutional, commercial and industrial customers, along with a successful acquisition strategy, National Waste has set its course to become a leading waste diversion company.
National Waste's 54-acre landfill facility located in Hernando, Florida, handles annual average disposals of roughly 240,000 cubic yards of construction debris annually. The site also offers an array of ancillary services such as roll-off dumpster services, mulching services and recycling. While the landfill facility is already permitted for future expansion, National Waste's growth strategy also calls for the opening of new satellite offices in counties and states that neighbor its existing operations.
In addition to increasing its geographic foothold, National Waste employs a strategic acquisition model to increase its overall market share. In 2015, the company acquired Gateway Rolloff Services LP and Waste Recovery Enterprises LLC, which are expected to generate a combined $3.8 million in annual revenue for National Waste moving forward. In the second quarter of 2016, National Waste added Sivart Services to its roster, creating an immediate source of additional revenue and expanding its foothold in the northeast area of New York.
Management has confirmed its interest in additional acquisition targets while demonstrating its ability to effectively integrate and organically grow the company's existing acquisition companies and maintain efficient operations. Disclaimer
National Waste Management Holdings, Inc. Company Blog
National Waste Management Holdings, Inc. News:
NetworkNewsWire Releases Exclusive Audio Interview with National Waste Management Holdings, Inc. (NWMH)
National Waste Management Holdings, Inc. (NWMH) Engages NetworkNewsWire for Corporate Communications Solutions
National Waste Management Holdings Inc. Reports 269% Increase in Third-Quarter Revenue
eXp World Holdings, Inc. (EXPI)
The QualityStocks Daily Newsletter would like to spotlight eXp World Holdings, Inc. (EXPI). Today, eXp World Holdings, Inc. closed trading at $4.0746, up 0.11%, on 14,409 volume with 23 trades. The stock’s average daily volume over the past 60 days is 19,516, and its 52-week low/high is $0.6101/$5.84.
eXp World Holdings, Inc. (EXPI) is the holding company for a number of businesses, most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage™. eXp Realty is a full-service real estate brokerage offering 24/7 access to a suite of collaborative tools, training features and socialization channels designed to meet the unique needs of real estate brokers and agents. By creating a fully-immersive, cloud office environment for real estate professionals, eXp effectively reduces agents' overhead, increases their profits and provides greater service value to consumers.
Through eXp Realty's innovative platform, agents and brokers are afforded the opportunity to earn equity in exchange for production and contributions to company growth. Additionally, eXp features an aggressive revenue sharing program that pays agents a percentage of the gross commission income earned by fellow professionals they recruit into the company. The result is a shared ownership community featuring a synergistic and collaborative group of forward-thinking, entrepreneurial professionals. With the emergence of the internet as the most powerful property marketing and advertising medium, eXp's internet and cloud technologies have helped thousands of consumers find, buy or sell homes without the need for a brick and mortar real estate office.
Since its launch in October 2009, eXp Realty has experienced rapid growth, with brokerage service now offered in 35 U.S. states and Alberta, Canada. In February 2016, the company officially welcomed its 1,000th real estate professional into its family of agent-owners, up from just 467 agents at the end of 2014. Following this achievement, the Agent-Owned Cloud Brokerage claimed a spot among the top 50 real estate brokerages in the United States based on agent count, according to data from RISMEDIA's 2015 PowerBroker 500 Report.
Similarly, eXp Realty generated record financial results during 2015. Following the launch of two new initiatives – including an online lead generation program and a stock compensation plan – the company achieved a 71 percent year-over-year increase in net revenues, recording $22.87 million for the year. As it continues to expand its footprint across North America, eXp Realty will look to leverage its unique agent-owned business model to continue attracting driven, entrepreneurial agents and real estate industry leaders while promoting sustainable financial growth. Disclaimer
eXp World Holdings, Inc. Company Blog
eXp World Holdings, Inc. News:
eXp World Holdings, Inc. Retains MZ Group as its Investor Relations Advisor
eXp Realty named the Number 2 Best Small Business Workplace in Oklahoma
Marsee Wilhems Team Joins eXp Realty in Tucson
OurPet's Company (OPCO)
The QualityStocks Daily Newsletter would like to spotlight OurPet's Company (OPCO). Today, OurPet's Company closed trading at $0.93, off by 2.11%, on 11,070 volume with 6 trades. The stock’s average daily volume over the past 60 days is 4,989, and its 52-week low/high is $0.6882/$1.06.
OurPet's Company (OPCO) develops, produces and markets various pet accessory and consumable products designed to awaken pets' natural instincts, be it in feeding, playing or waste management. Sold globally through pet specialty retailers, food, drug and mass chains, e-commerce and international channels, the company's products are marketed under a the OurPets®, Pet Zone® and PetTastic® brands with well-known sub-brands such as Play-N-Squeak™, Cosmic Catnip™, Durapet, SmartScoop and Flappy. In total, OurPet's has an intellectual property portfolio featuring more than 160 individual patents, giving the company sustainable access to the pet products industry for the foreseeable future.
In recent years, the U.S. pet products and services market has experienced strong growth, with total sales accounting for approximately $73 billion in 2014, according to a report by Packaged Facts. In 2015, this strong performance is expected to continue, building on the recent rise in related ecommerce purchases, as well as an uptick in dog and cat ownership throughout the country. In order to capitalize on this market performance, OurPet's maintains an ongoing new product development program to continually keep an evolutionary and revolutionary new product pipeline feeding its offerings. In July 2015, OurPet's introduced many new products at the national Super Zoo trade show in Las Vegas such as the Catty Whack®, Designer Diner™/Barking Bistro™ and the Zoom Plume™.
The company's capitalization strategy is guided by a management team of experienced industry professionals dedicated to further strengthening its product portfolio through aggressive development of innovative products. Management has a proven track-record of leveraging deep knowledge in the innovation, technology, distribution and pet markets to successfully push through adverse market conditions to achieve increases in revenue, margins and net income.
OurPet's, through its innovative and extensive line of popular pet products, is in a favorable strategic position to continue building upon its recent market growth. For prospective shareholders, this positioning makes the company an intriguing investment opportunity in the months to come. Look for OurPet's to capitalize on steady market performance moving forward, providing an opportunity for the company to realize strong investor returns in the future. Disclaimer
OurPet's Company Company Blog
OurPet's Company News:
OurPets(R) Switchgrass Natural Cat Litter(TM) Wins Pet Business 2016 Industry Recognition Award
OurPet's Company to Webcast, Live, at VirtualInvestorConferences December 1
OurPetís Company Reports Record Third Quarter 2016 Results
Singlepoint, Inc. (SING)
The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0125, even for the day, on 859,627 volume with 42 trades. The stock’s average daily volume over the past 60 days is 2,327,407, and its 52-week low/high is $0.0046/$0.0245.
Singlepoint, Inc. (SING) provides mobile technology and marketing solutions that enable companies, nonprofits and religious organizations to conduct business transactions, accept donations, and engage in targeted communication via mobile devices. Through diversification of its own model, the company is also leveraging its core technology to expand into the mobile auctions and daily fantasy sports markets.
SING currently has two fundraising solutions. Text2Bid is an interactive way to increase auction revenues. The technology makes it easy for people to bid in auctions from any text or web-enabled phone. Donate by Text allows nonprofits to securely collect one-time or recurring donations via text. This capability creates a personal experience for the donors, and enables ongoing communication between the donor and nonprofit or event sponsor.
SING's payment solutions include point-of-sale (POS) terminals, loyalty programs, payment processing, phone services and financing. Pay by Text™ enables a business to accept payment transactions and, in essence, turns the user's mobile phone into a point-of-sale device. Operating on the same platform as mobile marketing, Pay by Text is designed to increase revenues, raise the average per-transaction amount, and create a fast, easy and hassle-free method of payment.
As part of its diversification and expansion strategy, SING recently acquired an interest in DraftFury (www.draftfury.com), a company that offers skill-based NBA, NFL and MLB daily fantasy sports (DFS) contests. DraftFury is known for its innovative offerings and originality, and is the first cash-flow-positive DFS enterprise. This transaction places SING in a multi-billion dollar industry expected to generate entry fees of $14.4 billion in 2020. Under the guidance of a leadership team well-versed in technology, engineering, marketing and raising capital, SING anticipates a strong foothold in its chosen markets. Disclaimer
Singlepoint, Inc. Company Blog
Singlepoint, Inc. News:
MoneyTV with Donald Baillargeon, 12/16
SinglePoint Subsidiary Advances Initiatives ahead of Open Banking System in Cannabis Industry
Singlepoint, Inc. (SING) CEO Discusses Influx of Calls from Cannabis Dispensaries on MoneyTV with Donald Baillargeon
Today's Top 3
The QualityStocks Public Company Sponsor News